COMMUNIQUÉS West-GlobeNewswire
-
California Provider Organizations Earn Recognition from IHA for Healthcare Performance
11/12/2025 -
Changes to the Executive Management
11/12/2025 -
AB Science annonce une nouvelle publication sur Medrxiv mettant en évidence le bénéfice clinique du masitinib chez les patients atteints de Sclérose Latérale Amyotrophique avant toute perte complète de fonction
11/12/2025 -
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
11/12/2025 -
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
11/12/2025 -
Hundreds Gather in Seattle in Support of Increasing Access to Mental Health Services in King County at SOUND Behavioral Health’s Annual SOUND of Hope Gala
11/12/2025 -
SEMCAP Health Leads $25 Million Series D Investment in SafeinHome
11/12/2025 -
Merakris Therapeutics Chief Scientific Officer Dr. Roger Ilagan to Present at Innovations in Wound Healing Symposium
11/12/2025 -
Hypersante Introduces the 2026 Longevity and Biohacking Summit in Paris
11/12/2025 -
Les billets sont maintenant en vente pour Importance Vitale : sommet national sur la santé des femmes
11/12/2025 -
Vitally Important: National Women’s Health Summit Tickets On Sale Now
11/12/2025 -
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
11/12/2025 -
PatchMD Launches New Dopamine Support Patch for Natural Mood and Focus Support
11/12/2025 -
ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors
11/12/2025 -
Stryker declares an $0.88 per share quarterly dividend
11/12/2025 -
Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite Treatment
11/12/2025 -
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
11/12/2025 -
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
11/12/2025 -
Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
11/12/2025
Pages